Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Pfizer Inc. (PFE : NYSE)
 
 • Company Description   
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.

Number of Employees: 83,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $40.01 Daily Weekly Monthly
20 Day Moving Average: 24,050,416 shares
Shares Outstanding: 5,644.40 (millions)
Market Capitalization: $225,832.53 (millions)
Beta: 0.64
52 Week High: $56.32
52 Week Low: $39.23
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.59% -4.30%
12 Week -21.24% -24.32%
Year To Date -21.92% -23.85%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
66 HUDSON BOULEVARD EAST
-
NEW YORK,NY 10001
USA
ph: 212-733-2323
fax: 302-655-5049
None http://www.pfizer.com
 
 • General Corporate Information   
Officers
Albert Bourla - Chairman; Chief Executive Officer
David M. Denton - Chief Financial Officer; Executive Vice President
Jennifer B. Damico - Senior Vice President and Controller
James C. Smith - Director
James Quincey - Director

Peer Information
Pfizer Inc. (AGN.)
Pfizer Inc. (ABBV)
Pfizer Inc. (NVO)
Pfizer Inc. (LLY)
Pfizer Inc. (RHHBY)
Pfizer Inc. (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 717081103
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/22
Next Expected EPS Date: 05/02/23
Share - Related Items
Shares Outstanding: 5,644.40
Most Recent Split Date: 7.00 (3.00:1)
Beta: 0.64
Market Capitalization: $225,832.53 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 4.10%
Current Fiscal Quarter EPS Consensus Estimate: $1.00 Indicated Annual Dividend: $1.64
Current Fiscal Year EPS Consensus Estimate: $3.30 Payout Ratio: 0.24
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: -0.20
Estmated Long-Term EPS Growth Rate: 9.00% Last Dividend Paid: 01/26/2023 - $0.41
Next EPS Report Date: 05/02/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 12.12
Trailing 12 Months: 6.08
PEG Ratio: 1.35
Price Ratios
Price/Book: 2.34
Price/Cash Flow: 5.25
Price / Sales: 2.25
EPS Growth
vs. Year Ago Period: 5.56%
vs. Previous Quarter: -35.96%
Sales Growth
vs. Year Ago Period: 1.90%
vs. Previous Quarter: 7.30%
ROE
12/31/22 - 42.03
09/30/22 - 43.95
06/30/22 - 43.18
ROA
12/31/22 - 19.55
09/30/22 - 19.80
06/30/22 - 18.89
Current Ratio
12/31/22 - 1.22
09/30/22 - 1.59
06/30/22 - 1.42
Quick Ratio
12/31/22 - 1.00
09/30/22 - 1.37
06/30/22 - 1.20
Operating Margin
12/31/22 - 37.60
09/30/22 - 37.46
06/30/22 - 34.47
Net Margin
12/31/22 - 31.27
09/30/22 - 29.81
06/30/22 - 28.92
Pre-Tax Margin
12/31/22 - 34.62
09/30/22 - 33.37
06/30/22 - 31.74
Book Value
12/31/22 - 17.09
09/30/22 - 16.55
06/30/22 - 15.59
Inventory Turnover
12/31/22 - 3.53
09/30/22 - 3.53
06/30/22 - 4.02
Debt-to-Equity
12/31/22 - 0.34
09/30/22 - 0.35
06/30/22 - 0.39
Debt-to-Capital
12/31/22 - 25.53
09/30/22 - 26.00
06/30/22 - 28.17
 

Powered by Zacks Investment Research ©